[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580955":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":37,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"with primary outcome",null,"Patients with HFpEF who experienced primary outcome (were hospitalized for HF or died)",{"label":13,"type":10,"description":14,"interventionNames":10},"without primary outcome","Patients with HFpEF who survived without hospitalization for HF",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Artem G Ovchinnikov, MD, PhD, DSc","CONTACT","+74954146612","artcardio@mail.ru",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian Federation","RECRUITING","Moscow","121552","Russia",{"type":29,"coordinates":30},"Point",[31,32],37.61781,55.75204,{"lat":32,"lon":31},[35],{"name":36,"role":18,"phone":10,"phoneExt":10,"email":20},"Artem Ovchinnikov, MD, PhD, DSc",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100580955",false,"NCT06844032","Predictors of Poor Prognosis in HFpEF","Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n1. Signed and data informed consent;\n2. New York Heart Association (NYHA) class II-III heart failure;\n3. Left ventricular ejection fraction \\> 50%;\n4. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.\n\nExclusion Criteria:\n\n1. Evidence of myocardial ischemia during stress echocardiography;\n2. Significant lesions of the main coronary arteries;\n3. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);\n4. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;\n5. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);\n6. Primary pulmonary artery hypertension;\n7. Significant left-sided structural valve disease;\n8. Anemia (Hb \\\u003C 100 g\u002FL);\n9. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2 (CKD-EPI);\n10. Non-cardiac conditions that complicate\u002Fexclude participation in the study;\n11. Exacerbation of heart failure less than 3 months prior to study entry.","ALL","40 Years",{"count":48,"type":49},500,"ESTIMATED","OBSERVATIONAL","Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.",[53],"HFpEF",[53,55,56,57,58,59,60],"HF","diastolic dysfunction","left ventricle (LV) filling pressures","left ventricular hypertrophy","cardiac reserves","myocardial fibrosis","2026-04-14",{"date":63,"type":64},"2026-04-17","ACTUAL",{"date":66,"type":64},"2022-01-31",{"date":68,"type":49},"2026-12-31",{"name":5,"class":6},1]